News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Nivolumab with and without ipilimumab in solid tumors of high mutational burden – Journal for ImmunoTherapy of Cancer
Photo from pediatriconcall.com
Aug 9, 2024, 05:53

Nivolumab with and without ipilimumab in solid tumors of high mutational burden – Journal for ImmunoTherapy of Cancer

Journal for ImmunoTherapy of Cancer shared a post on X, about recent paper published in Journal for ImmunoTherapy of Cancer:

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Authors: Michael Schenker, Mauricio Burotto, Martin Richardet, Tudor-Eliade Ciuleanu, Anthony Gonçalves, Neeltje Steeghs, Patrick Schoffski, Paolo A. Ascierto, Michele Maio, Iwona Lugowska, Lorena Lupinacci, Alexandra Leary, Jean-Pierre Delord, Julieta Grasselli, David S. P. Tan, Jennifer Friedmann, Jacqueline Vuky, Marina Tschaika, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Georgia Kollia, Misena Pacius, Quyen Duong, Ning Huang, Parul Doshi, Jonathan Baden, Massimo Di Nicola.

Journal for ImmunoTherapy of Cancer

”New JITC article: Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.”

Journal for ImmunoTherapy of Cancer

Source: Journal for ImmunoTherapy of Cancer/X

Alexandra Leary Anthony Gonçalves cancer David S. P. Tan Georgia Kollia Iwona Lugowska Jacqueline Vuky Jean-Pierre Delord Jennifer Friedmann JITC Jonathan Baden Journal for ImmunoTherapy of Cancer Julieta Grasselli Lorena Lupinacci Marina Tschaika Martin Richardet Massimo Di Nicola Mauricio Burotto Michael Schenker Michele Maio Misena Pacius Neeltje Steeghs Ning Huang nivolumab OncoDaily Oncology Paolo A. Ascierto Parul Doshi Patrick Schöffski pilimumab Quyen Duong Ruta Slepetis Sai Vikram Vemula solid tumors Somasekhar Konduru Tudor-Eliade Ciuleanu
Special Coverage
Blog
Dec 21, 2024, 10:19
A Portrait of Germline Pathogenic Variants in Breast Cancer Genes in Brazil
Dialogues
Dec 21, 2024, 10:09
Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market
Blog
Dec 21, 2024, 09:22
When the world of science and sports comes together! - The V Foundation
Blog
Dec 21, 2024, 09:16
Timely cancer treatment isn’t just a goal, It’s a necessity - European Cancer Organisation
Science
Dec 21, 2024, 09:06
Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial
Blog
Dec 21, 2024, 09:00
Miriam Mutebi: Does Nipple and Areola Size Matter?
Science
Dec 21, 2024, 08:51
Wafik S. El-Deiry: Our recent review on Targeting the SMURF2-HIF1α axis
Science
Dec 21, 2024, 08:48
Oncology Brothers: Another ALK inhibitor gets FDA approval
Science
Dec 21, 2024, 08:42
Eric K. Singhi: Decoding clinical trial jargon
Science
Dec 21, 2024, 08:37
Gustavo Viani: The Role of Radiotherapy on the management of HCC
Science
Dec 21, 2024, 08:29
Bishal Gyawali: The case of cancer drug Xtandi
Blog
Dec 21, 2024, 08:18
Sami (Papacek) Mansfield: Why is muscle health so important among cancer survivers?